What Inventprise does

Inventprise is a clinical-stage biotechnology company founded in 2012 by Dr. Subhash Kapre and headquartered in Redmond, Washington, developing conjugate and other vaccines for infectious diseases with disproportionate burden in low- and middle-income countries. Its core platform is a proprietary Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker conjugation technology that enables high-valent vaccines (up to 25 serotypes) with reduced carrier suppression and broader serotype coverage than existing 10-20 valent pneumococcal conjugate vaccines. The lead candidate, IVT PCV-25, is in Phase 2 clinical evaluation, with a hexavalent Group B Streptococcus vaccine (IVT GBS-06) in Phase 1/2 and earlier-stage candidates targeting Shigella, Klebsiella, RSV (mRNA), COVID-19, and a dissolvable microneedle patch (D-MAP) delivery format.

The company operates over 100,000 square feet of manufacturing infrastructure, including a 70,000 sq ft highly automated cGMP facility in Woodinville, WA capable of producing tens of millions of doses annually, and offers contract manufacturing services to third parties. Its go-to-market motion is sales-led, targeting WHO prequalification and global health procurement channels (UNICEF, PAHO) with a stated commitment to LMIC-first launch at affordable pricing. The economic model is currently pre-revenue on products; the company is sustained by cumulative Bill & Melinda Gates Foundation program-related investment exceeding $100 million, with up to $90 million announced in November 2021 (first $30M tranche received April 2022). A November 2025 layoff of 76 employees reduced headcount to approximately 200 amid an ongoing clinical and infrastructure build-out.

Name

Inventprise

Legal name

Inventprise, LLC

Website

https://inventprise.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

51–100 employees

Short description

Inventprise is a clinical-stage biotechnology company developing high-valent conjugate and mRNA vaccines for infectious diseases prevalent in low- and middle-income countries, using a proprietary Hz-PEG-Hydrazide linker platform and 100,000+ sq ft of automated cGMP manufacturing capacity.

Ownership category

akta.pro rank

Product category

Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)

akta.pro secondary industries

Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

Keywords

• Conjugate vaccines
• Pneumococcal vaccines
• Vaccine manufacturing
• Bacterial vaccines
• MRNA vaccines

Headquarters

HQ city

Redmond

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Vaccine Product Sales: Inventprise is a clinical-stage vaccine invention company that will generate revenue through sales of its vaccine candidates once approved and commercialized. The company has committed to making IVT PCV-25 available at affordable prices to low- and middle-income countries through WHO prequalification and global health procurement channels (UNICEF, PAHO). Additional supply will be available for global demand outside LMICs.
2. Contract Manufacturing Services: Inventprise offers contract manufacturing services in biologics from process-to-end user, including process development, optimization, analytical services, and manufacturing from early clinical trials through commercialization. Services leverage expertise in protein purification, cell culture, conjugation chemistry, and automated commercial manufacturing.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Inventprise is a clinical-stage biotechnology company developing high-valent conjugate vaccines against infectious diseases with significant global health burden, using its proprietary Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker conjugation platform. Its pipeline includes IVT PCV-25 (25-valent pneumococcal conjugate vaccine), IVT GBS-06 (hexavalent Group B Streptococcal vaccine), Shigella and Klebsiella vaccine candidates, an mRNA RSV vaccine, and a dissolvable microneedle array patch (D-MAP) delivery technology. The company also operates over 100,000 square feet of cGMP manufacturing facilities in Washington State and offers contract manufacturing services for biologics.

Product overview

Inventprise is a clinical-stage vaccine invention company with a proprietary Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker conjugation technology platform. The company's product portfolio centers on high-valent conjugate vaccines targeting infectious diseases with significant global health burden. Core products include: IVT PCV-25 (25-valent pneumococcal conjugate vaccine in Phase 2 for adults and infants), IVT GBS-06 (hexavalent Group B Streptococcal vaccine for maternal immunization in Phase 1/2), IVT Shigella-04 (quadrivalent Shigella vaccine), IVT Klebsiella vaccine, and an mRNA RSV vaccine using Quantoom Biosciences' Ntensify technology. The company also develops a dissolvable microneedle array patch (IVT D-MAP) and has published preclinical results on a COVID-19 conjugate vaccine. Manufacturing capabilities span over 100,000 sq ft across Redmond and Woodinville, WA facilities with contract services offered to partners. The company was founded in 2012 by Dr. Subhash Kapre and is headquartered in Redmond, Washington with a European office in Switzerland.

Differentiator

Problem solved

Functional benefit

Products and services

• IVT PCV-25 25-valent pneumococcal conjugate vaccine for pediatric and adult populations, leveraging Inventprise's proprietary Hz-PEG-Hz linker conjugation platform to provide broader coverage (25 serotypes) against pneumococcal disease than existing vaccines covering 10-20 serotypes. Currently in Phase 2 clinical trials.
• IVT GBS-06 Hexavalent Group B Streptococcal (GBS) conjugate vaccine candidate for maternal immunization, covering serotypes Ia, Ib, II, III, V, and VII, representing approximately 99% of GBS serotypes causing stillbirth and 98-99% of early/late onset disease. Designed to prevent GBS disease in neonates and young infants.
• IVT Shigella-04 Quadrivalent Shigella conjugate vaccine candidate designed to reduce morbidity and mortality from shigellosis, which causes 80 million cases and 700,000 deaths annually, mostly in children under 5 in low- and middle-income countries. Supported by funding from the Bill & Melinda Gates Foundation.
• IVT Klebsiella Klebsiella vaccine candidate leveraging Inventprise's proprietary Hz-PEG-Hz conjugation platform, designed to reduce neonatal mortality from bacterial infections caused by Klebsiella pneumoniae and decrease emergence of antimicrobial resistance.
• mRNA RSV Vaccine Respiratory Syncytial Virus (RSV) mRNA vaccine candidate developed using Quantoom Biosciences' Ntensify midi system for mRNA production. Part of Inventprise's mRNA vaccine platform for rapid response to infectious diseases. Supported by Gates Foundation funding.
• COVID-19 Conjugate Vaccine Bivalent SARS-CoV-2 conjugate vaccine using proprietary Hz-PEG-Hz linker protein conjugation technology with detoxified diphtheria-derived carrier protein (rCRM197). Demonstrated broad neutralizing antibody responses across multiple SARS-CoV-2 variants in preclinical studies published in Vaccine Journal.
• IVT D-MAP Dissolvable Microneedle Array Patch (D-MAP) for vaccine delivery. Pain-free, easy to use, small in size (1 cm²) with potential for thermostability and elimination of cold-chain requirements. Multiple antigens can be included on one patch.
• Contract Manufacturing Services Comprehensive contract services including process development, clinical and commercial manufacturing, quality and regulatory programming, and automation design for biologics. Leverages subject matter expertise in protein purification, cell culture, conjugation chemistry, and automated commercial manufacturing.

Quantifiable outcome

• IVT PCV-25 targets 25 serotypes vs 10-15 in current licensed vaccines, addressing remaining pneumococcal disease burden
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Quantoom BiosciencescoreTechnology or Integration · 15 May 2025Inventprise selected Quantoom Biosciences' Ntensify midi system as core technology for its mRNA vaccine platform. The system enables production of high-yield, low-contaminant GMP-grade mRNA with scalable and automated solution from Phase I to commercial. As proof of concept, Inventprise is developing an RSV vaccine using this technology, supported by Gates Foundation funding.
• Wits Vaccines & Infectious Diseases Analytics (VIDA) Research UnitminorStrategic or Co-development Partner · 12 November 2024Wits VIDA in Johannesburg, South Africa is conducting the Phase 1/2 clinical study of Inventprise's hexavalent GBS vaccine candidate (IVT GBS-06). Prof. Shabir Madhi presented interim results at ISSAD 2026 in Nairobi, Kenya.
• Canadian Immunization Research Network (CIRN)minorStrategic or Co-development Partner · 10 November 2022Collaboration with CIRN for Phase 1/2 clinical evaluation of IVT PCV-25. Study conducted at Canadian Center for Vaccinology (Halifax), Vaccine Evaluation Center (British Columbia), Colchester Research Group (Nova Scotia), and Centre de recherche Saint-Louis (Quebec).
• PATHcoreStrategic or Co-development PartnerPATH (international nonprofit global health organization) collaborates with Inventprise on vaccine development, regulatory submissions (Health Canada), and technical support for IVT PCV-25. PATH has featured Inventprise's expanded-coverage pneumococcal vaccine in their publications.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Merck & Co. Merck's Prevnar 20 (20-valent PCV) is the established market leader in pneumococcal conjugate vaccines and is the comparator used in Inventprise's PCV-25 Phase 2 trials. Directly comparable in target indication and vaccine technology category, but at vastly larger scale with established commercial infrastructure.
• GSK: GSK has a competing PCV franchise (Synflorix) and acquired Affinivax for next-generation MAPS (Multiple Antigen Presenting System) vaccine technology. Comparable as a global vaccine manufacturer with overlapping pipeline in pneumococcal and other infectious disease vaccines.
• Pfizer: Pfizer developed the original Prevnar franchise and is developing higher-valent PCVs. As a top-2 incumbent in the pneumococcal vaccine market, Pfizer is the most direct competitive threat to Inventprise's PCV-25 positioning.
• Sanofi: Sanofi is a top-5 global vaccine manufacturer with broad portfolio including pediatric and adult vaccines. Comparable as a large incumbent with established global distribution and competing in similar infectious disease indications targeted by Inventprise's pipeline.
• Moderna: Moderna is the leading mRNA vaccine platform company. Inventprise's May 2025 selection of Quantoom's Ntensify system positions its mRNA platform in direct competition for pandemic preparedness contracts where speed-to-clinic is critical.

Direct peers

• Biological E: Biological E is an Indian vaccine manufacturer developing WHO-prequalified conjugate vaccines including PCVs targeting LMICs. Inventprise's VP of Manufacturing previously served as Associate VP-R&D at Biological E. Directly comparable as a high-volume, low-cost PCV competitor for global health procurement.
• Bharat Biotech: Bharat Biotech is an Indian vaccine manufacturer with WHO-prequalified vaccines and active PCV development. Comparable as an emerging global vaccine developer targeting similar LMIC markets and infectious disease indications with cost-competitive manufacturing.
• Novavax: Novavax is a clinical-to-commercial-stage vaccine developer using novel protein nanoparticle technology. Comparable as a non-incumbent vaccine developer focused on infectious diseases, with similar capital-intensive path to commercialization.
• Serum Institute of India: Inventprise founder Subhash Kapre previously led conjugate vaccine development at Serum Institute for 40 years. Serum Institute produces Pneumosil (10-valent PCV) and other conjugate vaccines at massive scale targeting LMICs, making it the most operationally and commercially comparable peer, particularly in WHO prequalification/LMIC tender dynamics.

Emerging players

• VBI Vaccines: VBI Vaccines is a clinical-stage vaccine developer with proprietary eVLP platform technology targeting infectious diseases including CMV and hepatitis B. Comparable as a small-cap vaccine developer with proprietary platform technology targeting similar disease areas, though at different stages.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/InventpriseLLC
• LinkedInlinkedin.com/company/inventprise-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inventprise